Landmark trial finds anal screening prevents cancer

The potentially practice-changing study shows treating precursor lesions reduces cancer in people with HIV
Professor Andrew Grulich
Professor Andrew Grulich.

Routine screening and removal of precursor lesions can significantly reduce the risk of anal cancer by nearly 60%, a world-first randomised controlled trial has found. 

The finding, from the Anal Cancer-HSIL Outcomes Research (ANCHOR) trial, suggests a test-and-treat approach should be the standard of care for high-risk groups, such as people living with HIV, the researchers say.